CR

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Retrieved on: 
목요일, 5월 9, 2024
NK, Investment, Lupus nephritis, Safety, Research, Cy, B cell, IND, Autoimmune disease, CD19, Cyclophosphamide, Patient, Cytopenia, NHL, SLE, Lymphoid leukemia, G&A, Investigational New Drug, Pharmaceutical industry

Nkarta expects to provide an update on first patient dosing for NKX019 in LN in the first half of 2024.

Key Points: 
  • Nkarta expects to provide an update on first patient dosing for NKX019 in LN in the first half of 2024.
  • In March 2024, Nkarta completed an underwritten offering of common stock and pre-funded warrants with gross proceeds of $240.1 million.
  • Nkarta had cash, cash equivalents, restricted cash, and investments in marketable securities of $450.0 million as of March 31, 2024.
  • Net loss was $29.5 million, or $0.58 per basic and diluted share, for the first quarter of 2024.

CentralReach Unveils CR ClaimCheckAI: the Only Fully-Integrated, Proprietary AI-Powered Solution Enabling Clean Claims for Autism and IDD Care Providers

Retrieved on: 
수요일, 5월 8, 2024
ABA, Risk, DSO, Spectrum, Quarantine, IDD, Artificial intelligence, Workflow, Audit

This is all done within CentralReach, eliminating the need to log into separate systems, transfer files, or perform any other suboptimal workflows that are required with a 3rd party solution.

Key Points: 
  • This is all done within CentralReach, eliminating the need to log into separate systems, transfer files, or perform any other suboptimal workflows that are required with a 3rd party solution.
  • As a result, customers will significantly reduce the number of claims denials, increase clean claims rates, and materially reduce audit risk, which will increase overall claims reimbursement rates and cash flow while reducing A/R and DSO levels.
  • "With increasing compliance mandates and payer scrutiny, improving claims performance is top of mind for all providers in the Autism and IDD Care market.
  • Key features and benefits of CR ClaimCheckAI include:
    Integrated AI Technology: Seamlessly checks all claims against updated payer rules and performs various compliance-related checks.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
월요일, 5월 6, 2024
FDA, Total, ITK, Research, PTCL, PR, Doctor of Philosophy, Webcast, Fungal infection, Atopic dermatitis, RCC, Lymphoma, Vanderbilt University Medical Center, Lung cancer, Conference call, Kidney cancer, Conference, CRS, Peripheral, Assistant, PRS, NSCLC, Patient, Safety, Pembrolizumab, Modified, CTCL, Time management, Clinical trial, Division, Sale, A2A, Adenosine, HNSCC, T-cell lymphoma, Nivolumab, Ipilimumab, B-cell lymphoma, Disease, ALCL, Physician, Head, PTCL-NOS, Pharmaceutical industry

BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  • Corvus anticipates initiating a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL in the third quarter of 2024.
  • Corvus will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the first quarter 2024 financial results.

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
월요일, 5월 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Retrieved on: 
월요일, 5월 6, 2024
FDA, University, City, Safety, University of Miami, Doctor of Philosophy, ADC, Patient, Diffuse large B-cell lymphoma, NHL, Toxicity, Therapy, Pharmaceutical industry

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).

Key Points: 
  • LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).
  • As of the data cutoff date of March 30, 2024, 15 patients were evaluable.
  • Of these 15 patients evaluated, 13 achieved a complete response (CR) and one patient achieved a partial response (PR).
  • “Based on the initial data from University of Miami’s Phase 2 trial evaluating ZYNLONTA in relapsed/refractory MZL, we are encouraged by the potential opportunity in the 2L+ setting for patients with this rare disease.”

Fairbanks Morse Defense Awarded Purchase Order for Common Rail Technology Retrofit Kit on San Antonio Class Ships

Retrieved on: 
화요일, 5월 7, 2024
Technology, Military, Machinery, Other Manufacturing, Maritime, Engineering, Green Technology, Transport, Government Technology, Other Defense, Contracts, Manufacturing, Software, Defense, Environment, Hardware, Electronic Design Automation, USS, USS Pittsburgh, OEM, Carbon, Navy, FMD, USS Harrisburg, Ingalls Shipbuilding, Ship, LPD, STC, Shipbuilding

Fairbanks Morse Defense (FMD), a portfolio company of Arcline Investment Management, has been awarded a purchase order by HII’s Ingalls Shipbuilding division to deliver an FM PC2.5 STC common rail technology retrofit kit, which will upgrade existing PC2.5 STC engines currently installed on U.S. Navy San Antonio-class amphibious transport dock ships.

Key Points: 
  • Fairbanks Morse Defense (FMD), a portfolio company of Arcline Investment Management, has been awarded a purchase order by HII’s Ingalls Shipbuilding division to deliver an FM PC2.5 STC common rail technology retrofit kit, which will upgrade existing PC2.5 STC engines currently installed on U.S. Navy San Antonio-class amphibious transport dock ships.
  • FMD's common rail fuel injection technology maximizes performance through enhanced fuel efficiency and reduced carbon emissions.
  • The high-pressure rail electronic fuel injection system can provide 5.5% fuel savings through improved fuel atomization with more complete and efficient combustion.
  • The four engines being assembled for the future LPD-32 will also include common rail technology.

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Retrieved on: 
금요일, 5월 3, 2024
FDA, Congress, Cancer, Urinary tract infection, Urinary diversion, Safety, Carcinoma, Survival, Johnson & Johnson, Immunotherapy, CRS, Abstract, Cohort, BCG, Disease, Bladder cancer, Dysuria, Patient, Metastasis, Medicine, NMIBC, AUA, Biopsy, BTD, Urination, Interim, Food and Drug Administration, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for, or decline, radical cystectomy. These data were featured today in a plenary session (Abstract #P2-01) at the 2024 American Urological Association Annual Meeting (AUA) taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • "These results address an area of high unmet need for bladder sparing therapies in this patient population."
  • Results included an evaluation of 85 patients (median age of 71 years old: range 40-88; 32.9% with concurrent papillary disease) who received TAR-200 monotherapy.
  • The centrally confirmed complete response (CR) rate was 82.8% by urine cytology and/or biopsy (95% confidence interval [CI], 70.6-91.4).
  • Seven patients (8.2%) had Grade 3 or higher TRAEs and four patients (4.7%) had one or more serious TRAEs.

Kura Oncology Reports First Quarter 2024 Financial Results

Retrieved on: 
목요일, 5월 2, 2024
FDA, Cancer, KURA, Investment, Venetoclax, HNSCC, Food, Prognosis, Research, Renal cell carcinoma, FTI, AML, Webcast, Disease, LDAC, Patient, Azacitidine, QT interval, BTD, Acute myeloid leukemia, FLT3, Head, Initiate, ID, Breakthrough therapy, Pharmaceutical industry

ET –

Key Points: 
  • ET –
    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2024 financial results and provided a corporate update.
  • Research and development expenses for the first quarter of 2024 were $36.3 million, compared to $25.2 million for the first quarter of 2023.
  • General and administrative expenses for the first quarter of 2024 were $18.2 million, compared to $11.4 million for the first quarter of 2023.
  • ET / 1:30 p.m. PT today, May 2, 2024, to discuss the financial results for the first quarter 2024 and to provide a corporate update.

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Retrieved on: 
화요일, 4월 23, 2024
Neuro-Oncology (journal), First grade, FDA, Society, University, BRAF V600, Day One, Hospital, Acne, Safety, Food, Biopharmaceutical, Conference call, Nausea, Insurance, Conference, Research, Webcast, Viral, Speech, Fatigue, Human, Disease, BRAF, Vomiting, Patient, Medicine, Headache, Event, Rash, Constipation, Diagnosis, Head, Neoplasm, Upper respiratory tract infection, PRS, Xeroderma, Fever, Caregiver, Ageing, Pharmaceutical industry

BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.

Key Points: 
  • With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.
  • “We are very proud that our first approved medicine addresses this serious and life-threatening disease of childhood and adolescence.
  • BRAF is the most commonly altered gene in pLGG, with up to 75 percent of children having a BRAF alteration.
  • “This is a tremendous moment not only for Day One, but also for the broader pediatric brain tumor community.

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Retrieved on: 
화요일, 4월 23, 2024
Oncology, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, UCLA, FDA, Cystoscopy, Safety, Food, Immunotherapy, Recurrence, Carcinoma in situ, Cystectomy, BCG, CIS, Patient, Medicine, NMIBC, Bacillus, Multimedia, Memory, Biology, Associate, Quality of life, Breakthrough therapy, NK, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240422820209/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240422820209/en/
    ImmunityBio’s ANKTIVA is approved for non-muscle invasive bladder cancer (Photo: Business Wire)
    “The FDA’s approval of ANKTIVA marks our launch of a next-generation immunotherapy beyond checkpoint inhibitors,” said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio.
  • This novel mechanism of action, which mimics the biology of the dendritic cell, begins the evolution of immunotherapy beyond T cells alone.
  • The combination of the proliferation of key cancer-killing immune cells, together with the activation of T cells with memory, results in durable complete responses.
  • The 77 evaluable patients in this single-arm, multicenter trial received ANKTIVA with BCG maintenance therapy for up to 37 months.